• Corpus ID: 4937890

Mechanism of action of antidepressants.

@article{Artigas2002MechanismOA,
  title={Mechanism of action of antidepressants.},
  author={Francesc Casa{\~n}as Artigas and David J. Nutt and Richard C. Shelton},
  journal={Psychopharmacology bulletin},
  year={2002},
  volume={36 Suppl 2},
  pages={
          123-32
        }
}
A wide range of effective drugs is available for the treatment of major depression. The discovery of these agents has not always been the result of rational drug design. Tricyclic antidepressants formed the mainstay of treatment until the 1990s, and selective serotonin reuptake inhibitors (SSRIs) have dominated treatment over the last decade. However, the poor tolerability associated with tricyclic antidepressants and concerns about the efficacy of SSRIs has led to the search for alternative… 

Figures from this paper

Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 – 2006

Despite mixed results from clinical trials with several NK1 antagonists, effective therapeutic agents for depression may still emerge from compounds with combined serotonin reuptake inhibitor/NK1 antagonist properties.

Review on Antidepressant Medication

Antidepressant drugs are the mainstay for the treatment of depression and are recommended as first line treatment options in moderate and severe depression or mild or sub threshold depression that has persisted despite other interventions.

Selective Serotonin Reuptake Inhibitors Potentiate the Rapid Antidepressant-Like Effects of Serotonin4 Receptor Agonists in the Rat

In acute conditions, the 5-HT4 agonist prucalopride was able to counteract the inhibitory effect of the selective serotonin reuptake inhibitors (SSRI) fluvoxamine and citalopram on 5- HT neuron impulse flow, in Dorsal Raphé Nucleus cells selected for their high basal discharge.

Antiparkinsonian Treatment for Depression in Parkinson's Disease: Are Selective Serotonin Reuptake Inhibitors Recommended?

The mechanism of action of SSRIs in the context of Parkinson's disease is considered by investigating the fall in the levels of serotonergic markers and the inhibitory outcomes of antiparkinsonian treatment onserotonergic nerve activity.

A comparative study on efficacy of amitriptyline and escitalopram in the treatment of depression

This study suggests that escitalopram is effective in the treatment of depression and its efficacy appears to be comparable to amitriptyline at the end of four weeks.

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature

Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning, and there is no evidence as yet that vortioxidant is more clinically effective than other types of antidepressants.

Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology

  • P. Nathan
  • Biology
    Journal of psychopharmacology
  • 2001
While reuptake inhibition may more than likely be responsible for most of the antidepressant effect, other mechanisms may also contribute alone or in combination to exert the overall antidepressant action.

Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases

Three main groups of diseases are considered, based on the evidence of monoamine involvement (schizophrenia, depression, obesity), the identification of monoamines in the diseases processes and the prospect of the involvement of monoaminergic mechanisms (epilepsy, Alzheimer's disease, stroke).
...

References

SHOWING 1-10 OF 39 REFERENCES

Mechanism of action of antidepressant medications.

  • J. Feighner
  • Psychology
    The Journal of clinical psychiatry
  • 1999
The new antidepressants, including the single-receptor selective serotonin reuptake inhibitors (SSRIs) and multiple-re receptor antidepressants venlafaxine, mirtazapine, bupropion, trazodone, and nefazodone are discussed.

Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine.

  • S. Kasper
  • Psychology, Medicine
    Journal of clinical psychopharmacology
  • 1997
Efficacy findings from the limited number of comparative clinical trials conducted in this patient population were reviewed, and the contention that tricyclic antidepressants offer superior efficacy to the SSRIs and the reversible monoamine oxidase inhibitors in the treatment of severe depression is supported.

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

  • J. Kent
  • Biology, Psychology
    The Lancet
  • 2000

Rapid onset of action of venlafaxine

  • S. Montgomery
  • Psychology, Medicine
    International clinical psychopharmacology
  • 1995
It is important to evaluate a new antidepressant in terms of its efficacy in relation to that of reference agents such as the tricyclics and monoamine oxidase inhibitors. Newer antidepressants have

Brain noradrenaline and the mechanisms of action of antidepressant drugs

  • T. Svensson
  • Psychology, Biology
    Acta psychiatrica Scandinavica. Supplementum
  • 2000
From this review emerges the notion that facilitation of brain noradrenergic neurotransmission may represent a more fundamental means to achieve maximal response in major depression than hitherto understood.

Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants.

The results suggest that the neurobiological mechanisms underlying the antidepressant responses to different drugs involve alterations in the functioning of different neurotransmitter systems and reinforce the importance of changes in both the serotonin and catecholamine systems for successful antidepressant responses.

Noradrenergic approaches to antidepressant therapy.

Clinicians now have a range of antidepressants with variable neurotransmitter effects, different side effect profiles, and some interesting differences in functional utility in their armamentarium for treating depression, renewed interest in the role of neurotransmitters other than serotonin in the treatment of depression.

Drug-Drug Interactions Involving Antidepressants: Focus on Venlafaxine

  • L. Ereshefsky
  • Biology, Medicine
    Journal of clinical psychopharmacology
  • 1996
In vitro and in vivo data indicate that venlafaxine either does not significantly inhibit or weakly inhibits the activity of isoenzymes CYP2C9, CYD2D6, CYP1A2, or CYP3A3/4, which is a major role in the metabolism of many commonly used drugs.

Overview of antidepressants currently used to treat anxiety disorders.

  • J. Feighner
  • Psychology
    The Journal of clinical psychiatry
  • 1999
Newer antidepressants, such as mirtazapine, nefazodone, and venlafaxine XR, may provide some benefits across the broad spectrum of anxiety disorders with the safety and tolerability that are the hallmarks of third generation antidepressants.